Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes

被引:326
作者
Cohen, Cyrille J. [1 ,2 ]
Gartner, Jared J. [2 ]
Horovitz-Fried, Miryam [1 ]
Shamalov, Katerina [1 ]
Trebska-McGowan, Kasia [2 ]
Bliskovsky, Valery V. [3 ]
Parkhurst, Maria R. [2 ]
Ankri, Chen [1 ]
Prickett, Todd. D. [2 ]
Crystal, Jessica S. [2 ]
Li, Yong F. [2 ]
El-Gamil, Mona [2 ]
Rosenberg, Steven A. [2 ]
Robbins, Paul F. [2 ]
机构
[1] Bar Ilan Univ, Goodman Fac Life Sci, Lab Tumor Immunol & Immunotherapy, IL-5290002 Ramat Gan, Israel
[2] NCI, Surg Branch, NIH, Bethesda, MD 20892 USA
[3] NCI, Lab Canc Biol & Genet, NIH, Bethesda, MD 20892 USA
关键词
MUTATIONAL LANDSCAPE; METASTATIC MELANOMA; CD4+T CELLS; CANCER; ANTIGENS; CD4(+); RECOGNITION; BLOCKADE; THERAPY; TCR;
D O I
10.1172/JCI82416
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
100103 [病原生物学]; 100218 [急诊医学];
摘要
Adoptively transferred tumor-infiltrating T lymphocytes (TILs) that mediate complete regression of metastatic melanoma have been shown to recognize mutated epitopes expressed by autologous tumors. Here, in an attempt to develop a strategy for facilitating the isolation, expansion, and study of mutated antigen-specific T cells, we performed whole-exome sequencing on matched tumor and normal DNA isolated from 8 patients with metastatic melanoma. Candidate mutated epitopes were identified using a peptide-MHC-binding algorithm, and these epitopes were synthesized and used to generate panels of MHC tetramers that were evaluated for binding to tumor digests and cultured TILs used for the treatment of patients. This strategy resulted in the identification of 9 mutated epitopes from 5 of the 8 patients tested. Cells reactive with 8 of the 9 epitopes could be isolated from autologous peripheral blood, where they were detected at frequencies that were estimated to range between 0.4% and 0.002%. To the best of our knowledge, this represents the first demonstration of the successful isolation of mutation-reactive T cells from patients' peripheral blood prior to immune therapy, potentially providing the basis for designing personalized immunotherapies to treat patients with advanced cancer.
引用
收藏
页码:3981 / 3991
页数:11
相关论文
共 51 条
[1]
Selected Murine Residues Endow Human TCR with Enhanced Tumor Recognition [J].
Bialer, Gil ;
Horovitz-Fried, Miryam ;
Ya'acobi, Shlomo ;
Morgan, Richard A. ;
Cohen, Cyrille J. .
JOURNAL OF IMMUNOLOGY, 2010, 184 (11) :6232-6241
[2]
Targeting cancer-specific mutations by T cell receptor gene therapy [J].
Blankenstein, Thomas ;
Leisegang, Matthias ;
Uckert, Wolfgang ;
Schreiber, Hans .
CURRENT OPINION IN IMMUNOLOGY, 2015, 33 :112-119
[3]
Properties of MHC Class I Presented Peptides That Enhance Immunogenicity [J].
Calis, Jorg J. A. ;
Maybeno, Matt ;
Greenbaum, Jason A. ;
Weiskopf, Daniela ;
De Silva, Aruna D. ;
Sette, Alessandro ;
Kesmir, Can ;
Peters, Bjoern .
PLOS COMPUTATIONAL BIOLOGY, 2013, 9 (10)
[4]
Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR [J].
Cohen, CJ ;
Zheng, ZL ;
Bray, R ;
Zhao, YB ;
Sherman, LA ;
Rosenberg, SA ;
Morgan, RA .
JOURNAL OF IMMUNOLOGY, 2005, 175 (09) :5799-5808
[5]
Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy [J].
Coulie, Pierre G. ;
Van den Eynde, Benoit J. ;
van der Bruggen, Pierre ;
Boon, Thierry .
NATURE REVIEWS CANCER, 2014, 14 (02) :135-146
[6]
Desai Dattatraya V, 2014, Methods Mol Biol, V1184, P333, DOI 10.1007/978-1-4939-1115-8_19
[7]
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma [J].
Dudley, ME ;
Wunderlich, JR ;
Yang, JC ;
Sherry, RM ;
Topalian, SL ;
Restifo, NP ;
Royal, RE ;
Kammula, U ;
White, DE ;
Mavroukakis, SA ;
Rogers, LJ ;
Gracia, GJ ;
Jones, SA ;
Mangiameli, DP ;
Pelletier, MM ;
Gea-Banacloche, J ;
Robinson, MR ;
Berman, DM ;
Filie, AC ;
Abati, A ;
Rosenberg, SA .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (10) :2346-2357
[8]
Giudicelli Veronique, 2011, Cold Spring Harb Protoc, V2011, P695, DOI 10.1101/pdb.prot5633
[9]
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens [J].
Gubin, Matthew M. ;
Zhang, Xiuli ;
Schuster, Heiko ;
Caron, Etienne ;
Ward, Jeffrey P. ;
Noguchi, Takuro ;
Ivanova, Yulia ;
Hundal, Jasreet ;
Arthur, Cora D. ;
Krebber, Willem-Jan ;
Mulder, Gwenn E. ;
Toebes, Mireille ;
Vesely, Matthew D. ;
Lam, Samuel S. K. ;
Korman, Alan J. ;
Allison, James P. ;
Freeman, Gordon J. ;
Sharpe, Arlene H. ;
Pearce, Erika L. ;
Schumacher, Ton N. ;
Aebersold, Ruedi ;
Rammensee, Hans-Georg ;
Melief, Cornelis J. M. ;
Mardis, Elaine R. ;
Gillanders, William E. ;
Artyomov, Maxim N. ;
Schreiber, Robert D. .
NATURE, 2014, 515 (7528) :577-+
[10]
Incorporation of Transmembrane Hydrophobic Mutations in the TCR Enhance Its Surface Expression and T Cell Functional Avidity [J].
Haga-Friedman, Astar ;
Horovitz-Fried, Miryam ;
Cohen, Cyrille J. .
JOURNAL OF IMMUNOLOGY, 2012, 188 (11) :5538-5546